Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Shannon Kelley Sells 1,077 Shares of Company Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Shannon Kelley sold 1,077 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $400.00, for a total value of $430,800.00. Following the completion of the transaction, the general counsel directly owned 10,397 shares of the company’s stock, valued at approximately $4,158,800. This trade represents a 9.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madrigal Pharmaceuticals Trading Down 0.1%

Shares of MDGL stock opened at $399.63 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $353.54 and a fifty-two week high of $615.00. The company has a 50 day moving average price of $486.74 and a 200 day moving average price of $497.41. The stock has a market capitalization of $9.23 billion, a P/E ratio of -66.83 and a beta of -0.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%. During the same quarter in the prior year, the company posted ($5.08) EPS. Equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -3.78 EPS for the current fiscal year.

Madrigal Pharmaceuticals News Roundup

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Analysts Set New Price Targets

MDGL has been the subject of a number of research reports. Truist Financial restated a “buy” rating and set a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a research report on Wednesday. UBS Group reissued a “buy” rating and set a $735.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. Barclays decreased their target price on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. The Goldman Sachs Group began coverage on Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price objective on the stock. Finally, Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $706.87.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. William Blair Investment Management LLC boosted its position in shares of Madrigal Pharmaceuticals by 4.0% during the 3rd quarter. William Blair Investment Management LLC now owns 337,035 shares of the biopharmaceutical company’s stock worth $169,852,000 after purchasing an additional 12,912 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Madrigal Pharmaceuticals by 2.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 50,545 shares of the biopharmaceutical company’s stock valued at $25,473,000 after purchasing an additional 1,251 shares during the period. Fifth Third Bancorp raised its holdings in Madrigal Pharmaceuticals by 3.5% during the third quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 28 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in Madrigal Pharmaceuticals by 17.3% during the 3rd quarter. Maryland State Retirement & Pension System now owns 1,098 shares of the biopharmaceutical company’s stock worth $553,000 after buying an additional 162 shares during the period. Finally, Ritholtz Wealth Management purchased a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at $200,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.